MolMed is a drug company, and since July 2003 it is formally authorised for the production and release of medicinal products for human use, in compliance with current Good Manufacturing Practice (cGMP) standards. MolMed has an in-house GMP facility of approximately 1400 sqm, completely redesigned in 2006 and validated by the National health authority in July 2007, and including six aseptic clean rooms, a fermentor area, and a separate Research laboratory. At present, the GMP facility meets both European and US GMP requirements.

MolMed's quality policy is designed to strictly follow the international cGMP guidelines. All operations are performed following Standard Operating Procedures (SOP) managed by the Quality Assurance Division.

Each product batch for clinical use is tested by Quality Control and formally released by the Qualified Person.